Samsung Electronics Co., Ltd.

Hyundai Motor Company

Ajou University Industry-Academic Cooperation Foundation

Kia Corporation

Imdpharm Inc.

Kia Motors Corporation

Korea Institute of Science and Technology

Rihu Healthcare Co., Ltd.

Young-Joon Park

Jung-Gun You

Ji-Yong Ha

Myung-Yoon Um

Jeong-Hyo Lee

Jun-sun Hwang

Jun-Ho Park

Yun-Hoon Choung

Sung-Nam Baek

Pan-Sang Kim

Sang-Hyuk Mun

Hyung-Mook Yoon

Byng-Mo Jeon

Je-Ha Son

Seung-Hwan Lee

Young Sun Kim

Young Sung Kim

Young Kyu Oh

Il Joong Hwang

Kyung-Ho Shin

Hong-Wook Lee

Chul-Ho Yu

Chulho Yu

Yoonho Cho

Ga Hui Oh

Jae-geun Ha

Chang-Dong Kim

Sung Moon Oh

Sook Choi

Seong-Wook Moon

Chan-Ki Min

Hye-Kil Hwang

Sung-Woo Nam

Minsun Chang

Sang-won Jeon

Sung-Sik Kong

Won-Seok Jun

Joon-Young Hong

Sang-Won Jeon

Woo-Young Lee

Kyung-Il Lee

Disclosed herein are an emergency operating system and an emergency operating method for a hybrid vehicle with a damaged bearing of an engine, which are capable of preventing a bearing from being further damaged due to a drive motor and a hybrid starter and generator (HSG) when damage to the bearing installed in an engine is detected and capable of driving the hybrid vehicle and which include a bearing damage detection operation, an engine driving maintaining operation, a first state of charge (SOC) comparison operation, and a first emergency operating operation.

Emergency operating system and method for hybrid vehicle with damaged bearing of engine

Provided is a sustained-release lipid pre-concentrate in the form of a lipid solution, including an unsaturated fatty acid having 14 to 20 carbon atoms (C14˜C20); a phospholipid; and α-tocopherol acetate, wherein the sustained-release lipid pre-concentrate is free of diacyl glycerol and sorbitan unsaturated fatty acid ester; and forms a liquid crystal in an aqueous medium. Further provided is a sustained-release injectable pharmaceutical composition in the form of a lipid solution, including the pre-concentrate and a pharmacologically active substance, wherein the sustained-release injectable pharmaceutical composition is free of diacyl glycerol and sorbitan unsaturated fatty acid ester.

Sustained-release lipid preformulation and pharmaceutical composition for sustained-release injection in form of lipid solution containing same

Provided are a semiconductor device and a method for fabricating the same. The semiconductor device includes an active fin protruding upwardly from a substrate and extending in a first direction and a gate structure extending in a second direction intersecting to cross the active fin, where a first width of a lower portion of the gate structure that contacts the active fin is greater than a second width of the lower portion of the gate structure that is spaced apart from the active fin.

Semiconductor devices having gate structures with skirt regions

A composition for preventing or treating hearing loss, containing aleaf extract as an active ingredient, is disclosed. A pharmaceutical composition for preventing or treating hearing loss, containing the extract (aleaf extract) as an active ingredient, protects auditory hair cells in the cochlea and spiral ganglion cells from damage caused by noise and the like and effectively reduces the hearing threshold measured in the auditory nerves, thereby being usable as an agent for preventing or treating hearing loss.

Composition for preventing or treating hearing loss, containingleaf extract as active ingredient

A method for sensing damage to a bearing of an engine using a vibration signal may sense the damage to the bearing even without a sensor for directly sensing the damage to the bearing using a frequency signal input to a knocking sensor from the engine for each traveling state (acceleration traveling, cruise traveling, deceleration traveling) of a vehicle.

Method for sensing damage to bearing of engine

The present invention relates to a pharmaceutical composition, containing sarpogrelate or a pharmaceutically acceptable salt thereof as an active ingredient, for preventing, alleviating, or treating sensorineural hearing loss. The sarporgrelate according to the present invention protects against hearing loss caused by noise through the suppression of auditory cell apoptosis and the expression increase of antioxidant enzyme in auditory cells, and thus can be advantageously used in the prevention and alleviation of sensorineural hearing loss.

Composition, containing sarpogrelate as active ingredient, for preventing or treating sensorineural hearing loss

Provided is a method of preventing and treating a dry eye syndrome comprising administering a pharmaceutical composition comprising sulglycotide or its pharmaceutically acceptable salt as an active ingredient.

Pharmaceutical composition containing sulglycotide or pharmaceutically acceptable salt thereof for preventing or treating dry eye

Provided is a composition for preventing and treating a menopausal disorder containing extracts ofLEV. as an active ingredient. Specifically, the extracts ofLEV. exhibit a significant ER agonist activity within a cell, and exhibit a very potent ER agonist (full agonist) activity with an ECvalue of about 100 &#x3bc;g/ml. Thus, the extracts ofLEV. comprising a high content of plant metabolites similar to estrogen can be useful as hormone replacement therapy capable of improving various symptoms derived from a deficiency of estrogen in menopausal women.

Composition for preventing and treating climacteric disorder containing extracts ofLEV. as active ingredient

A semiconductor device and a method of manufacturing a semiconductor device, the device including an active fin protruding from a substrate and extending in a first direction, a first device isolation region disposed at a sidewall of the active fin and extending in a second direction, the second direction crossing the first direction, a normal gate electrode crossing the active fin, a first dummy gate electrode having an undercut portion on the first device isolation region, the first dummy gate electrode extending in the second direction, and a first filler filling the undercut portion on the first device isolation region, wherein the undercut portion is disposed at a lower portion of the first dummy gate electrode.

Fin semiconductor device including dummy gate on isolation layer

A structure of an exterior door strip includes a mounting portion mounted to an outer side of a outer door panel positioned, and a SUS trim coupled to an outer side of the mounting portion, and including: a first mounting portion formed in a longitudinal direction and having an end piece; a bridge connected to an other end of the first mounting portion; and a second mounting portion connected to the other end of the bridge and having a screw hole, in which the first mounting portion, the bridge, and the second mounting portion are integrally formed, and torque caused by screw engagement of the second mounting portion is not transmitted to the first mounting portion, thereby resolving a problem regarding quality in external appearance of the vehicle, preventing corrosion caused by rain water, and reducing production costs of the vehicle.

Exterior door strip assembly

A method of controlling a CVVT may include a) checking whether a predetermined time has passed, after engine starts. b) locking an actuator by driving oil control valve with different driving currents in accordance with whether a predetermined time has passed after the engine starts. c) unlocking the actuator or feed-backing control cam phase in accordance with whether the actuator is unlocked. d) feed-backing control cam phase or locking the actuator by driving oil control valve with predetermined current in accordance with whether control cam phase is not reached before the actuator is locked. e) driving the oil control valve with predetermined current to maintain the control cam phase or turning off the oil control valve, after feed-backing control cam phase or locking the actuator by driving the oil control valve with predetermined current in accordance with whether the control cam phase is not reached before the actuator is locked.

Method of controlling CVVT according to current control for oil control valve

A fabrication method of a magnetic tunnel junction includes the steps of: forming a magnetic tunnel junction constructed having a first magnetic layer, a tunnel barrier formed at an upper surface of the first magnetic layer and a second magnetic layer formed at an upper surface of the tunnel barrier; and thermally treating the junction rapidly for 5 seconds&#x2dc;10 minutes at a temperature of 200&#x2dc;600&#xb0; C. to re-distribute oxygens in the tunnel barrier and make the interface between the tunnel barrier and the magnetic layer to be even. The tunneling magnetoresistance and thermal stability of the magnetic tunnel junction can be improved through the rapid thermal annealing.

Magnetic tunneling junction and fabrication method thereof

Growing community of inventors

Seoul, South Korea

Young-Joon Park